{"id":"NCT04249687","sponsor":"Galderma R&D","briefTitle":"Treatment of Moderate to Severe Lateral Canthal Lines","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-10","primaryCompletion":"2020-09-25","completion":"2021-02-10","firstPosted":"2020-01-31","resultsPosted":"2023-06-18","lastUpdate":"2023-06-18"},"enrollment":303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lateral Canthal Lines"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin","otherNames":["QM1114-DP"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.","primaryOutcome":{"measure":"Percentage of Subjects With a â‰¥ 2-grade Improvement From Baseline on the Lateral Canthal Line Investigator and Subject Assessments at Maximum Smile at One Month.","timeFrame":"Month 1","effectByArm":[{"arm":"Treatment","deltaMin":106,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":230},"commonTop":["Injection site bruising","COVID-19","Sinusitis","Headache","Nasopharyngitis"]}}